Pharmacological modulation of inflammation
Inflammation is a physiological process activated in response to various pathological situations. However, chronic inflammation in tissues or the abnormal response of inflammatory cells have been identified as pathological elements in many diseases, such as cancer, Alzheimer’s disease or atherosclerosis. Pharmacological modulation of inflammation in these contexts represents a therapeutic approach in these highly prevalent diseases.
Aim
Discovery and characterization of natural or synthetic molecules with inflammation modulating activity in different cell types and pathological settings.
We use a wide variety of in vitro assays to study the effects of compounds on various manifestations of inflammatory processes. As cellular models, we use primary human endothelial cells, and inflammatory cells such as human monocytes/macrophages and lymphocytes.
The Sponge-Derived Brominated Compound Aeroplysinin-1 Impairs the Endothelial Inflammatory Response through Inhibition of the NF-κB Pathway.
Vidal I, Castilla L, Marrero AD, Bravo-Ruiz I, Bernal M, Manrique I, R Quesada A, Medina MÁ, Martínez-Poveda B.
Marine Drugs., 2022 Sep 26;20(10):605. PMID: 36286429; PMCID: PMC9605425..
UMA18-FEDERJA-220
Estudio del potencial farmacológico de compuestos anti-angiogénicos para el tratamiento de la aterosclerosis.
Noviembre 2019 - Noviembre 2022
Junta de Andalucía – FEDER
PID2019-105010RB-I00
Angiogenesis, inflammation and metabolism as therapeutic targets for pathological angiogenesis using biotechnological approaches.
Enero 2020 - Diciembre 2022
MICINN
